Member Info for oxygen

I’m under the impression that Ed Milliband’s rhetoric is increasing becoming more extreme, as he see’s the continuing attacks on his Net Zero fantasy land hitting home. This will hopefully just help to widen the distance between himself and those with more moderate views, the likes of Rachel Reeves would seem to hold. At least Labours manifesto will show where the real power lies in this particular arena, and I’d be surprised if it’s not wearing a skirt !

Well let’s hope she doesn’t take us down any rabbit holes, otherwise she’ll be known as Bunny !

Re: SG&A, it’s very easy to spend others money, someone ie. the CFO, needs to get this under control rather quickly otherwise you’ll hear a new CFO saying his focus is on cost control !

Remember Nat R. bought 60,000 shares at over £4 a couple of years ago, so even then he saw value, we’ve moved up a few gears since so every chance you’ll get your wish !

Having read all those Risk Factors attached to the sale of Accredited, think I’ll pass on that offer plus not a fan of legacy portfolio’s that can deteriorate with age !

Guess she’ll pass that over to the Group Communications Director, that’s presuming he’s still with us as seems remarkably quiet for someone with that title !

“Everything Alistar said can now be disregarded” ….you mean this as well in his last dying breath ..“ Avacta has been able to leverage this excellent progress in the clinic to progress conversations with potential commercial partners “. I think many are now left wondering who to believe, it certainly ain’t the Chairman !

Don’t forget CEO’s don’t act in isolation, there is a Chairman and Board of Directors all of whom have input. Guess the good news is I can’t see the likes of CC discussing progress with the likes of Vox Markets !

Disappointed AS has been ousted, CC turns the language down and DX to go. Just hope CC ‘s business skills match her scientific ones. Meanwhile the CFO and Chairman ( don’t worry about funding ) escape….hmm, not impressed. Shall now review my investment here.

Good to see a little momentum leading into YE Results, but still some way to go before a review of holding is required. We first need to hit Jefferies target !

Sell prior to news usually works well, AS rarely disappoints !

Yes shame Nasdaq is currently a pipe dream, we’d be able to report in Dollars which always looks better, albeit would be quite a challenge for our CFO.

I’m sure ML will manage this to obtain valve for money, not create temporary SP spikes that only fall once they depart.

Seems Merrills now need to get a move on with only a 2 month window granted .

Old trader. Hope you cast your vote accordingly at the AGM , I certainly will !

Interesting article in the Times today, about Zandy Forbes, the eccentric CEO of MeiraGTx, another promising UK biotech. Her comments resonate here;

“Would she have floated on the LSE, if she had her time again? Absolutely not, she says. Small biotechs are risky, “money-burning endeavours,” she says. Meira, for example, invests in developing new medicines, but does not sell any treatments to patients yet.

While US pension funds and hedge funds have spent two decades gaining expertise in how to evaluate and invest in such drug developers, UK investors are simply not prepared to fund those risks.”

And as we’ve found out !

PL. Many companies get away with Placings at much thinner discounts to the prevailing SP, why because their perceived risk factors are much lower, ours clearly aren’t in the eyes of those approached for funding support who will have studied all availability Data.. Professional investors are merely cold and calculated, unlike most retail investors who buy and suddenly fall in love with the stock, often losing substantial capital thus would be more appropriate to describe them as ‘clueless ‘. Witness the level of passion on this BB when finding AS has strung them along yet again, or heaven forbid someone has gone Short !

And that’s the continuing conundrum, the recent Placing that will have involved many with knowledge in this field,

haven’t shown the same enthusiasm towards the emerging data. Guess many bear the scars of previous CT’s that haven’t quite lived up to expectations!

Are you sure they weren’t referring to the Moderna/MSD trials involving vaccine mRNA-4157 (V940), being the world’s first personalised mRNA cancer jab for melanoma, and likely other cancers, which is still in trials. Just highlights we need to get a move on !

Naturally we all talk from an Investors perspective, many working to develop new areas of science their motivation can be quite different. AS doesn’t strike me as someone who’s only interested in financial gain thus this vehicle we’re in may not hold the resale valve some expect !